- Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Li BCM, Huh SM, Prieto MD, Hong G, Schwarz C, Moss RB, Quon BS.J Allergy Clin Immunol Pract. 2021 Jan 14:S2213-2198(21)00056-8. doi: 10.1016/j.jaip.2020.12.064. Online ahead of print.
- Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons. Moss RB.J Allergy Clin Immunol. 2021 Jan 30:S0091-6749(21)00156-1. doi: 10.1016/j.jaci.2021.01.017. Online ahead of print.
- Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F.Lancet Respir Med. 2021 Jan 28:S2213-2600(20)30517-8. doi: 10.1016/S2213-2600(20)30517-8. Online ahead of print.